Aflibercept day preparations
Posted in Announcement, News
Aflibercept biosimilars
With the upcoming release of aflibercept biosimilars, we have generated a number of reports to help trusts monitor their current usage and prepare for the switch.
The report* Aflibercept intravitreal Actual Product use shows a detailed view of the current products being used and will start to show the biosimilar uptake as the months progress. Also the Aflibercept intravitreal biosimilar use will show total biosimilar vs original product use irrespective of the brand or brand of biosimilar.
The reports are essential for pharmacy teams wanting to track prescribing trends and readiness for biosimilar adoption as well as benchmark uptake against regional and national peers. The data will also be used at national level for monitoring.
Call to Action:
As part of this, and to ensure we provide you the best information possible, we have reviewed all pharmacy system descriptions for aflibercept and found that 44% do not specify the brand name in the description. Currently all these items are mapped to the Eylea brand but if the same description is used for the biosimilar products, the data becomes irregular and can no longer be used to…
Read more